Early convalescent plasma use — helpful in avoiding severe COVID — also may lower long COVID risk
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions — commonly known as long COVID — if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.
The new research, first posted online today in mBio, a journal from the American Society for Microbiology, is a follow-up investigation to the 2021 clinical trial that showed convalescent plasma ...











